Bioventus Inc. raised earnings guidance for the twelve months ending December 31, 2023. For the period, the company now expects net sales to be between $498 million to $505 million, an increase in the midpoint from company's previous guidance of $490 million to $505 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.735 USD | +2.41% |
|
-3.78% | +6.26% |
05-07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
05-07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.26% | 357M | |
+75.69% | 12.57B | |
+12.50% | 7B | |
-30.50% | 6.78B | |
+9.11% | 5.2B | |
-19.88% | 4.67B | |
+19.81% | 4.26B | |
-21.04% | 3.84B | |
-28.39% | 2.7B | |
-1.73% | 1.98B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Raises Earnings Guidance for the Twelve Months Ending December 31, 2023